Description
FLYA13 has been developed together with FLYRD18 for packaging of retroviruses, it is especially useful for in vivo gene therapy. Both cell lines have been derived from HT1080 cells. FLYA13 has been transfected with Moloney murine leukaemia virus cores with envelope glycoproteins of amphotropic murine leukaemia virus. This cell line cell line is able to produce human complement-resistant retroviral vectors at titres consistently higher than 1x10,000,000 i.u./ml. Addition of 4µg/ml blasticidin S and 10µg/ml phleomycin into the media may enhance the packaging function. No replication competent virus has been detected in this cell line.
Adherent Suspension
Adherent
Suggested Medium
DMEM + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).
Quality Control
FLYA13 Cell Line was tested and found to be free of mycoplasma, bacterial, viruses, and other toxins. All cells were above 95% viability before freezing.
Morphology
Epithelial-like
Shippment
FLYA13 Cell Line will be shipped using dry ice.
Storage
Store the cell lines in liquid nitrogen vapor (less than -130°C)
Warranty
FLYA13 Cell Line is for research use only
